ラティゴ・バイオセラピューティクス
LTGO
Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded on November 20, 2018 and is headquartered in Thousand Oak, CA.
| 期間 | EPS | 売上 | FCF |
|---|---|---|---|
| 2026 Q3 | -0.55 | $0 | -$20M |
| 2026 Q2 | -0.43 | $0 | -$21M |
| 2026 Q1 | -0.52 | $0 | -$27M |
| 2025 Q4 | 0.00 | $0 | -$35M |